GMI-1271 Restores Velcade’s Punch Against Myeloma in Mice, Study Reports
GlycoMimetics’ GMI-1271 restored the punch of the myeloma treatment Velcade (bortezomib) in mice, which should rekindle hope in patients who failed to respond to…
News
Phase 1 Actimab-M Trial at Baylor Recruiting Heavily Treated Myeloma Patients
Multiple myeloma patients who received at least three prior lines of therapy and whose cancer expresses the CD33 molecule may enroll in the recently opened…
Janssen to Discuss New Combinations of Darzalex and Other Multiple Myeloma Therapies
Janssen Biotech will discuss at a Chicago cancer conference the effectiveness of new multiple myeloma treatment combinations that include its therapy Darzalex (daratumumab). The…
Multiple Myeloma Marathon Runner Don Wright, 76, Races Again in Philadelphia
Don Wright, the 76-year-old marathon runner who recently reached his goal of running 100 marathons after being diagnosed with multiple myeloma, ran Philadelphia’s Miles for…
Microfluidic Device May Replace Bone Marrow Biopsies for Myeloma
Patients with multiple myeloma soon may be diagnosed and followed solely with the use of a blood sample, avoiding the painful process of collecting a…
FDA Grants Tasquinimod Orphan Drug Status to Treat Multiple Myeloma
The small molecule immunomodulatory drug tasquinimod has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment of multiple…
Hematologist-Oncologist to Lead Innovative NYU Bone Marrow Transplant Initiative
Syrian-born hematologist-oncologist Ahmad Samer Al-Homsi, MD, MBA, will lead an innovative program at NYU Langone’s Perlmutter Cancer Center for treating blood cancers, including multiple…
Amgen Applies to FDA Requesting Approval of Xgeva to Treat Multiple Myeloma
Amgen submitted a supplemental Biologics Licence Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of Xgeva…
Genetically Modified KITE-585 Therapy Increases Survival in Mice with Myeloma, Study Shows
Kite Pharma’s genetically modified T-cell therapy KITE-585 has delayed tumor progression and increased survival in mice with multiple myeloma, according to a preclinical-trial study. The…
Stem Cell Transplant with 3-Drug Combo Improved Progression-Free, But Not Overall Myeloma Survival
Treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD), in addition to a stem cell transplant, improved progression-free survival among multiple myeloma patients…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML